Specificity requirement for FDC and concomitant medication [Bioanalytics]

posted by qualityassurance – 2023-07-07 11:06 (682 d 11:43 ago) – Posting: # 23659
Views: 2,497

Hi Karthik,

My opinion is that your validation should mimic the actual study condition. In BE studies of FDC, plasma samples contains all the analytes of interest and hence CC/QC during validation should contain the other analyte at ULOQ concentration or cmax concentration.

What is opinion of other (bioanalytical) experts?

Regards,
qualityassurance

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,681 registered users;
88 visitors (0 registered, 88 guests [including 10 identified bots]).
Forum time: 22:50 CEST (Europe/Vienna)

Mediocrity knows nothing higher than itself,
but talent instantly recognizes genius.    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5